Research for immunotherapy of glioblastoma with autologous heat shock protein gp96

Trial Profile

Research for immunotherapy of glioblastoma with autologous heat shock protein gp96

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs HSP Gp96 vaccine (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cure&Sure Biotech
  • Most Recent Events

    • 10 Dec 2015 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top